<i>Sox6</i> is expressed and needed in erythropoietic tissues of adult mice under physiological conditions. by Bogdan Dumitriu (244216)

“…<p>(<b>A</b>) Northern blot of RNA from liver at embryonic day 14.5 (E14.5), and marrow and spleen at 6, 10, and 20 weeks. …”

ELISA kit information. by Shuailin Li (11907158)

“…Furthermore, in AN-LSCs, travoprost treatment does not lead to a decrease in NF-κB and ADH7 protein levels.</p></div>…”

Table_1_The impact of China's zero markup drug policy on drug costs for managing Parkinson's disease and its complications: an interrupted time series analysis.docx by Ruilin Wang (1452577)

“…</p>Methods<p>The drug costs for managing PD and its complications per outpatient visit or inpatient stay were estimated using electronic health data from a tertiary hospital in China from January 2016 to August 2018. …”

Phenotypic and Genetic Correlations of Feed Efficiency Traits with Growth and Carcass Traits in Nellore Cattle Selected for Postweaning Weight by Thais Matos Ceacero (3044547)

“…The variance components were estimated by the restricted maximum likelihood method using a two-trait animal model. The heritability estimates (h²) were 0.14, 0.24, 0.20, 0.22, 0.19, 0.15, 0.11 and 0.11 for gain:feed, RFI, RFI_b, RFI_sf, RG, RIG, RIG_b and RIG_sf, respectively. …”

Role of the Trifluoropropynyl Ligand in Blue-Shifting Charge-Transfer States in Emissive Pt Diimine Complexes and an Investigation into the PMMA-Imposed Rigidoluminescence and Rigi... by Jackson S. McCarthy (13034930)

“…The increase in Φ_PL upon incorporation into PMMA film (rigidoluminescence) results from a decrease in the rate constant for non-radiative relaxation. …”

Integrated analysis of promoter mutation, methylation and expression of <i>AKT1</i> gene in Chinese breast cancer patients by Jianfu Heng (3842491)

“…In clinicopathological factor analysis, <i>AKT1</i> showed significant hypo-methylation (<i>P</i> = 0.0249) and suppressed expression (<i>P</i> = 0.0375) in HER2 negative subtype. And a trend of decrease in expression level (<i>P</i> = 0.0624) of <i>AKT1</i> in the ER negative subtype was observed, which is significantly decreased in basal-like breast tumor (<i>P</i> = 0.0328).…”

Data_Sheet_1_Aldosterone-Induced Sarco/Endoplasmic Reticulum Ca2+ Pump Upregulation Counterbalances Cav1.2-Mediated Ca2+ Influx in Mesenteric Arteries.docx by Rogelio Salazar-Enciso (12228458)

“…Altogether, Ca_v1.2, SERCA pump, RyRs, and BK_Ca channels work as a functional unit at the PM-SR nanodomain, regulating intracellular Ca²⁺ and vascular function. …”

DataSheet_1_Associations of chest X-ray trajectories, smoking, and the risk of lung cancer in two population-based cohort studies.docx by Ya Liu (205636)

“…However, the associations of CXR trajectories, smoking and LC risk remain unknown.</p>Methods<p>A total of 52,486 participants from the PLCO and 22,194 participants from the NLST were included. …”

The levels of secretion of endogenous and exogenous proteins are affected by SECReTE strength. by Osnat Cohen-Zontag (6900233)

“…<p><b>(A) SECReTE enhances the ability to grow on sucrose.…”

Simulations of multiple regulators with different weights and heterogeneous <i>K</i>_{<i>n</i>,<i>i</i>} (related to Fig 4). by Xiangrui Ji (16705908)

“…(C) The deletion of inhibitors is equivalent to a decrease in the division threshold. If the threshold change is small, e.g., <i>inh3</i>Δ, <i>V</i>_<i>b</i> is still proportional to the equivalent threshold so that the CV of <i>V</i>_<i>b</i> remains constant. …”

Transition Metal Complexes with Sulfur Ligands. 130. Synthesis, Structure, and Reactivity of the Sulfur-Rich Ruthenium Hydride Complexes [Ru(H)(PR₃)(‘S₄')]<su... by Dieter Sellmann (2539633)

“…They were isolated as [Li(THF)(Et₂O)][Ru(H)(PR₃)(‘S₄')] (R = ⁱPr (<b>1a</b>), Cy (<b>1b</b>), Na[Ru(H)(PCy₃)(‘S₄')]·2BEt₃·0.5DMSO (<b>2a</b>), and the solvent-free Na[Ru(H)(PPh₃)(‘S₄')]·2BEt₃ (<b>2b</b>). …”

Impacts of winter climate change on northern forest understory carbon dioxide exchange determined by reindeer grazing by Noora Kantola (14263490)

“…CO2 concentration (ppm), relative humidity (%), and temperature (℃) during each manual measurement were logged every 5 sec for 2 min with a handheld logger (model MI70, Vaisala Inc.). NEE and ER were calculated from the linear change of the CO₂ concentration in the chamber by the ideal gas equation, and gross ecosystem productivity (GEP) was obtained by subtracting ER from NEE.…”

Lung-Sparing Surgery for Treatment of Pulmonary Metastases: VATS Right Anterior Segmentectomy (S3) and RLL Wedge Resection by Andres Obeso (4544185)

“…By contrast, centrally located lesions usually require more extensive resections which may be necessary to obtain a complete excision. In these cases, lung-sparing techniques are preferable so as to preserve healthy pulmonary tissue and decrease minimally the pulmonary function in case future pulmonary resections are needed. …”

Mixed Ligand Copper(II) Complexes of <i>N</i>,<i>N</i>-Bis(benzimidazol-2-ylmethyl)amine (BBA) with Diimine Co-Ligands: Efficient Chemical Nuclease and Protease Activities and Cyto... by Rangasamy Loganathan (2081950)

“…Interestingly, the 5,6-dmp complex <b>3</b> is selective in exhibiting a positive induced CD band (ICD) upon binding to DNA suggesting that it induces a B to A conformational change. …”

The funnel plot of visual analog scale score. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

Intervention characteristics of included studies. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

GRADE evaluation of evidence quality. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

PRISMA flow diagram. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

Summary data and analyses. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

The funnel plot of Harris hip score. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”